OncoMatch/Clinical Trials/NCT06839001
CRYoablation for Small Tumors As Local Treatment - SIX Trial
Is NCT06839001 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for breast cancer.
To demonstrate the non-inferiority of cryoablation compared to breast surgery for the local treatment of early-stage breast cancer and to conduct a cost-minimization analysis comparing direct costs between treatments.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 expression
Complete pathological report (including results for ER, PR, HER2, Ki-67, and FISH report for the ERBB2 gene, if necessary)
Required: PR (PGR) expression
Complete pathological report (including results for ER, PR, HER2, Ki-67, and FISH report for the ERBB2 gene, if necessary)
Required: HER2 (ERBB2) expression
Complete pathological report (including results for ER, PR, HER2, Ki-67, and FISH report for the ERBB2 gene, if necessary)
Required: HER2 (ERBB2) amplification
FISH report for the ERBB2 gene, if necessary
Required: MKI67 expression
Complete pathological report (including results for ER, PR, HER2, Ki-67, and FISH report for the ERBB2 gene, if necessary)
Prior therapy
Cannot have received: neoadjuvant systemic therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify